A phase I proof-of-concept study of two formulations of epinephrine for the treatment of anaphylaxis, or severe allergic reaction

Trial Profile

A phase I proof-of-concept study of two formulations of epinephrine for the treatment of anaphylaxis, or severe allergic reaction

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Epinephrine (Primary) ; Epinephrine
  • Indications Anaphylaxis
  • Focus Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 12 Dec 2017 New trial record
    • 07 Dec 2017 According to a company media release, the first patient has been enrolled in this trial. INSYS expects enrollment in the study to be complete in the first quarter of 2018, with initial results for all enrolled patients available by February.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top